DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

To join this study, you need to be an adult, at least 18 years old. Your cancer must have a specific genetic change involving something called the 'MET gene'. This means doctors would have identified a METex14 skipping mutation, MET amplification, MET fusion, or another MET activating mutation in your cancer cells using special tests. These tests are usually done on a sample of your cancer.

Beyond these main points, there are other detailed health requirements that need to be checked to make sure it's safe for you to take part. For women who could become pregnant, you'll need to have a negative pregnancy test and agree to use highly effective birth control during the study and for 7 days after your last dose of medication. For men with female partners who could become pregnant, you'll need to use a condom or avoid sexual activity during the study and for 7 days after your last dose, to avoid fathering a child.

If you decide to take part, the first step involves your medical team looking at your cancer's genetic information to see if it matches the study requirements. If it does, you'll go through screening tests, including giving blood samples and possibly a biopsy, for research purposes. Once approved, you will start taking the study drug, capmatinib. You'll continue to take capmatinib until your cancer worsens, you experience side effects that are too difficult to manage, or you decide to stop participating. During your treatment, you'll have blood samples taken regularly, and another at the end of your treatment. After you finish treatment, you'll have follow-up check-ups every 3 months for two years to monitor your health.